NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$24.16
+0.16 (+0.67%)
Close of Nov 06, 2026 · end-of-day data
VCYT 8-K filings in 2025
Every material Form 8-K Veracyte filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Veracyte reported third-quarter 2025 results on November 4, 2025, with total revenue up 14% to $131.9 million and GAAP net income of $19.1 million, up from $15.2 million a year earlier. The company raised its full-year 2025 total revenue and testing revenue guidance, which signals higher expected sales for shareholders, though GAAP results included a $6.7 million loss tied to the deconsolidation of Veracyte SAS.
Total revenue rose to $131.9 million from $115.9 million; testing revenue rose 17% to $127.8 million.
GAAP net income was $19.1 million, or $0.24 per diluted share, versus $15.2 million, or $0.19, a year earlier; results included a $6.7 million loss from the deconsolidation of Veracyte SAS.
Full-year 2025 total revenue guidance was raised to $506 million to $510 million from $496 million to $504 million.
Adjusted EBITDA was $39.7 million, or 30.1% of revenue, compared with 23.6% a year earlier.
Veracyte reported second-quarter 2025 total revenue of $130.2 million, up 14% year over year, and swung to a GAAP net loss of $1.0 million after a $20.5 million impairment tied to its French subsidiary. The company raised its full-year testing revenue guidance and initiated full-year total revenue guidance of $496 million to $504 million, which matters to shareholders because it signals higher expected sales while the one-time charge weighs on reported profit.
Q2 2025 total revenue was $130.2 million, up 14% from $114.4 million; testing revenue was $122.3 million, up 14%.
GAAP net loss was $1.0 million, compared with net income of $5.7 million in Q2 2024, including a $20.5 million impairment charge.
Full-year 2025 testing revenue guidance was raised to $477 million to $483 million from $470 million to $480 million; total revenue guidance is $496 million to $504 million.
Non-GAAP diluted EPS was $0.44, up from $0.30 a year earlier; adjusted EBITDA was $35.8 million, or 27.5% of revenue.
At its June 17, 2025 annual meeting, Veracyte stockholders approved an amendment adding 2,500,000 shares to the 2023 Equity Incentive Plan and elected all seven director nominees. Stockholders also ratified Ernst & Young LLP as auditor for 2025 and approved future say-on-pay votes every year. The plan amendment passed with 50,604,131 votes for and 19,070,837 against, so the larger share reserve adds potential dilution for existing holders.
Plan amendment adds 2,500,000 shares of common stock to the 2023 Equity Incentive Plan; approved 50,604,131 for, 19,070,837 against, 15,258 abstain
All seven director nominees elected to serve until the 2026 annual meeting
Ernst & Young LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2025
Stockholders approved holding non-binding say-on-pay votes every year; next frequency vote expected at the 2031 annual meeting
Veracyte reported first-quarter 2025 total revenue of $114.5 million, up 18% from a year earlier, and net income of $7.0 million, compared with a net loss of $1.9 million in the same quarter of 2024. The company reiterated its 2025 testing revenue guidance of $470 million to $480 million and raised its adjusted EBITDA margin outlook to 22.5% from 21.6%, but it also said its French subsidiary Veracyte SAS has entered collective proceedings in a Marseille commercial court and that the parent will no longer fund that entity.
Total revenue $114.5 million, up 18%; testing revenue $107.3 million, up 19%
Net income $7.0 million, or $0.09 diluted per share, versus a net loss of $1.9 million a year earlier
2025 adjusted EBITDA margin guidance raised to 22.5% from 21.6%; testing revenue guidance reiterated at $470 million to $480 million
Veracyte SAS court process expected to finish by end of 2025; the company recorded $3.8 million of related expense in the quarter
Veracyte reported fourth-quarter 2024 revenue up 21% to $118.6 million and full-year 2024 net income of $24.1 million, compared with a net loss in 2023. The company is considering ending funding for its French subsidiary, Veracyte SAS, which could lead to bankruptcy proceedings after a works council consultation unless a buyer is found, and it is not providing total company revenue guidance for 2025.
Q4 2024 total revenue $118.6 million, up 21%; testing revenue $112.2 million, up 24%
Q4 2024 net income $5.1 million, diluted EPS $0.06; full-year 2024 net income $24.1 million, diluted EPS $0.31
2025 testing revenue guidance $470 million to $480 million; no total revenue guidance due to Marseille, France uncertainty
Veracyte SAS may begin bankruptcy proceedings after works council consultation if no funding or buyer is identified
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Veracyte filing is on SEC EDGAR ↗. 8-K briefs of other companies →